• Craig M McDonald, Heather Gordish-Dressman, Erik K Henricson, Tina Duong, Nanette C Joyce, Sanjay Jhawar, Mika Leinonen, Fengming Hsu, Anne M Connolly, Avital Cnaan, Richard T Abresch, and CINRG investigators for PubMed.
• University of California Davis Health, Sacramento, CA, USA. Electronic address: cmmcdonald@ucdavis.edu.
• Neuromuscul. Disord. 2018 Nov 1; 28 (11): 897-909.

AbstractWe describe changes in pulmonary function measures across time in Duchenne muscular dystrophy patients treated with glucocorticoids (GCs) > 1 year compared to GC naïve patients in the Cooperative International Research Group Duchenne Natural History Study, a multicenter prospective cohort study. 397 participants underwent 2799 pulmonary function assessments over a period up to 10 years. Fifty-three GC naïve participants (< 1 month exposure) were compared to 322 subjects with > 1 year cumulative GC treatment. Forced vital capacity (FVC), peak expiratory flow rate (PEFr), maximal inspiratory and expiratory pressures were performed and calculated as a percent predicted (%p). GC treatment slowed the rate of pulmonary decline as measured by FVC%p, in patients aged 7-9.9 years. GC treatment slowed 12 and 24-month progression of percent predicted spirometry to a greater degree in those with baseline FVC%p from < 80-34%. GC treatment resulted in higher peak absolute FVC and PEFr values with later onset of decline. Progression to an absolute FVC < 1 liter was delayed by GC treatment. Patients who reached a FVC below 1 L were 4.1 times more likely to die (p = 0.017). Long-term glucocorticoid treatment slows pulmonary disease progression in Duchenne dystrophy throughout the lifespan.Copyright © 2018 The Authors. Published by Elsevier B.V. All rights reserved.

25 keywords...

hide…